Claudins in Cancer Biology

Current Topics in Membranes

Volumn 65, Issue C, 2010, Pages 293-333

  Valle, Blanca L ^a   Morin, Patrice J ^a,b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Cancer; Claudin; Clostridium perfringens enterotoxin; Prognosis; Regulation diagnosis; Therapy

Indexed keywords

EID: 77954643393     PISSN: 10635823     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1063-5823(10)65013-2     Document Type: Book

References (235)

1. Agarwal R., D'Souza T., Morin P.J. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Research 2005, 65(16):7378-7385.
2. Agarwal R., Mori Y., Cheng Y., Jin Z., Olaru A.V., Hamilton J.P., et al. Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells. PLoS ONE 2009, 4(11):e8002.
3. Aldred M.A., Huang Y., Liyanarachchi S., Pellegata N.S., Gimm O., Jhiang S., et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. Journal of Clinical Oncology 2004, 22(17):3531-3539.
4. Al Moustafa A.E., Alaoui-Jamali M.A., Batist G., Hernandez-Perez M., Serruya C., Alpert L., et al. Identification of genes associated with head and neck carcinogenesis by cDNA microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene 2002, 21(17):2634-2640.
5. Aono S., Hirai Y. Phosphorylation of claudin-4 is required for tight junction formation in a human keratinocyte cell line. Experimental Cell Research 2008, 314(18):3326-3339.
6. Arabzadeh A., Troy T.C., Turksen K. Changes in the distribution pattern of Claudin tight junction proteins during the progression of mouse skin tumorigenesis. BMC Cancer 2007, 7(196).
7. Aung P.P., Mitani Y., Sanada Y., Nakayama H., Matsusaki K., Yasui W. Differential expression of claudin-2 in normal human tissues and gastrointestinal carcinomas. Virchows Archiv 2006, 448(4):428-434.
8. Banan A., Zhang L.J., Shaikh M., Fields J.Z., Choudhary S., Forsyth C.B., et al. Theta Isoform of protein kinase C alters barrier function in intestinal epithelium through modulation of distinct claudin isotypes: A novel mechanism for regulation of permeability. The Journal of Pharmacology and Experimental Therapeutics 2005, 313(3):962-982.
9. Banz C., Ungethuem U., Kuban R.J., Diedrich K., Lengyel E., Hornung D. The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. Fertility and Sterility 2009, [Epub ahead of print].
10. Bello I.O., Vilen S.T., Niinimaa A., Kantola S., Soini Y., Salo T. Expression of claudins 1, 4, 5, and 7 and occludin, and relationship with prognosis in squamous cell carcinoma of the tongue. Human Pathology 2008, 39(8):1212-1220.
11. Bignotti E., Tassi R.A., Calza S., Ravaggi A., Romani C., Rossi E., et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy. Gynecologic Oncology 2006, 103(2):405-416.
12. Billings S.D., Walsh S.V., Fisher C., Nusrat A., Weiss S.W., Folpe A.L. Aberrant expression of tight junction-related proteins ZO-1, claudin-1 and occludin in synovial sarcoma: An immunohistochemical study with ultrastructural correlation. Modern Pathology 2004, 17(2):141-149.
13. Blackman B., Russell T., Nordeen S.K., Medina D., Neville M.C. Claudin 7 expression and localization in the normal murine mammary gland and murine mammary tumors. Breast Cancer Research 2005, 7(2):R248-R255.
14. Blanchard A.A., Skliris G.P., Watson P.H., Murphy L.C., Penner C., Tomes L., et al. Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Archiv 2009, 454(6):647-656.
15. Boireau S., Buchert M., Samuel M.S., Pannequin J., Ryan J.L., Choquet A., et al. DNA-methylation-dependent alterations of claudin-4 expression in human bladder carcinoma. Carcinogenesis 2007, 28(2):246-258.
16. Borlak J., Meier T., Halter R., Spanel R., Spanel-Borowski K. Epidermal growth factor-induced hepatocellular carcinoma: Gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 2005, 24(11):1809-1819.
17. Burek M., Forster C.Y. Cloning and characterization of the murine claudin-5 promoter. Molecular and Cellular Endocrinology 2009, 298(1-2):19-24.
18. Carrozzino F., Soulie P., Huber D., Mensi N., Orci L., Cano A., et al. Inducible expression of Snail selectively increases paracellular ion permeability and differentially modulates tight junction proteins. American Journal of Physiology Cell Physiology 2005, 289(4):C1002-C1014.
19. Chang T.L., Ito K., Ko T.K., Liu Q., Salto-Tellez M., Yeoh K.G., et al. Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology 2010, 138(1):255-265. e1-3.
20. Chao Y.C., Pan S.H., Yang S.C., Yu S.L., Che T.F., Lin C.W., et al. Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. American Journal of Respiratory and Critical Care Medicine 2009, 179(2):123-133.
21. Chen Y., Lu Q., Schneeberger E.E., Goodenough D.A. Restoration of tight junction structure and barrier function by down-regulation of the mitogen-activated protein kinase pathway in ras-transformed Madin-Darby canine kidney cells. Molecular Biology of the Cell 2000, 11(3):849-862.
22. Chen S.P., Zhou B., Willis B.C., Sandoval A.J., Liebler J.M., Kim K.J., et al. Effects of transdifferentiation and EGF on claudin isoform expression in alveolar epithelial cells. Journal of Applied Physiology 2005, 98(1):322-328.
23. Cheung S.T., Leung K.L., Ip Y.C., Chen X., Fong D.Y., Ng I.O., et al. Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clinical Cancer Research 2005, 11(2 Pt 1):551-556.
24. Chiba T., Kawachi H., Kawano T., Kumagai J., Kitagaki K., Sekine M., et al. Independent histological risk factors for lymph node metastasis of superficial esophageal squamous cell carcinoma; implication of claudin-5 immunohistochemistry for expanding the indications of endoscopic resection. Diseases of the Esophagus 2009, [Epub ahead of print].
25. Choi Y.L., Kim J., Kwon M.J., Choi J.S., Kim T.J., Bae D.S., et al. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histology and Histopathology 2007, 22(11):1185-1195.
26. Choi Y.D., Kim K.S., Ryu S., Park Y., Cho N.H., Rha S.H., et al. Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma. Journal of Korean Medical Science 2007, 22(2):305-310.
27. Cohn M.L., Goncharuk V.N., Diwan A.H., Zhang P.S., Shen S.S., Prieto V.G. Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms. Journal of Cutaneous Pathology 2005, 32(8):533-536.
28. Colegio O.R., Van Itallie C.M., McCrea H.J., Rahner C., Anderson J.M. Claudins create charge-selective channels in the paracellular pathway between epithelial cells. American Journal of Physiology Cell Physiology 2002, 283(1):C142-C147.
29. Comper F., Antonello D., Beghelli S., Gobbo S., Montagna L., Pederzoli P., et al. Expression pattern of claudins 5 and 7 distinguishes solid-pseudopapillary from pancreatoblastoma, acinar cell and endocrine tumors of the pancreas. American Journal of Surgical Pathology 2009, 33(5):768-774.
30. Cunningham S.C., Kamangar F., Kim M.P., Hammoud S., Haque R., Iacobuzio-Donahue C.A., et al. Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions. Cancer Epidemiology, Biomarkers and Prevention 2006, 15(2):281-287.
31. Darido C., Buchert M., Pannequin J., Bastide P., Zalzali H., Mantamadiotis T., et al. Defective claudin-7 regulation by Tcf-4 and Sox-9 disrupts the polarity and increases the tumorigenicity of colorectal cancer cells. Cancer Research 2008, 68(11):4258-4268.
32. Davidson B., Zhang Z., Kleinberg L., Li M., Florenes V.A., Wang T.L., et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clinical Cancer Research 2006, 12(20 Pt 1):5944-5950.
33. de Oliveira S.S., de Oliveira I.M., De Souza W., Morgado-Diaz J.A. Claudins upregulation in human colorectal cancer. FEBS Letters 2005, 579(27):6179-6185.
34. Dhawan P., Singh A.B., Deane N.G., No Y., Shiou S.R., Schmidt C., et al. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. The Journal of Clinical Investigation 2005, 115(7):1765-1776.
35. Dos Reis P.P., Bharadwaj R.R., Machado J., Macmillan C., Pintilie M., Sukhai M.A., et al. Claudin 1 overexpression increases invasion and is associated with aggressive histological features in oral squamous cell carcinoma. Cancer 2008, 113(11):3169-3180.
36. D'Souza T., Agarwal R., Morin P.J. Phosphorylation of claudin-3 at threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells. The Journal of Biological Chemistry 2005, 280(28):26233-26240.
37. D'Souza T., Indig F.E., Morin P.J. Phosphorylation of claudin-4 by PKCepsilon regulates tight junction barrier function in ovarian cancer cells. Experimental Cell Research 2007, 313(15):3364-3375.
38. Dufresne J., Cyr D.G. Activation of an SP binding site is crucial for the expression of claudin 1 in rat epididymal principal cells. Biology of Reproduction 2007, 76(5):825-832.
39. Ebihara C., Kondoh M., Hasuike N., Harada M., Mizuguchi H., Horiguchi Y., et al. Preparation of a claudin-targeting molecule using a C-terminal fragment of Clostridium perfringens enterotoxin. The Journal of Pharmacology and Experimental Therapeutics 2006, 316(1):255-260.
40. Facchetti F., Lonardi S., Gentili F., Bercich L., Falchetti M., Tardanico R., et al. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Archiv 2007, 451(3):669-680.
41. Fluge O., Bruland O., Akslen L.A., Lillehaug J.R., Varhaug J.E. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 2006, 16(2):161-175.
42. Folpe A.L., Billings S.D., McKenney J.K., Walsh S.V., Nusrat A., Weiss S.W. Expression of claudin-1, a recently described tight junction-associated protein, distinguishes soft tissue perineurioma from potential mimics. American Journal of Surgical Pathology 2002, 26(12):1620-1626.
43. Foss C.A., Fox J.J., Feldmann G., Maitra A., Iacobuzio-Donohue C., Kern S.E., et al. Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: Initial imaging in experimental models of pancreatic cancer. Molecular Imaging 2007, 6(2):131-139.
44. French A.D., Fiori J.L., Camilli T.C., Leotlela P.D., O'Connell M.P., Frank B.P., et al. PKC and PKA phosphorylation affect the subcellular localization of claudin-1 in melanoma cells. International Journal of Medical Sciences 2009, 6(2):93-101.
45. Fritzsche F.R., Oelrich B., Johannsen M., Kristiansen I., Moch H., Jung K., et al. Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. Clinical Cancer Research 2008, 14(21):7035-7042.
46. Fujibe M., Chiba H., Kojima T., Soma T., Wada T., Yamashita T., et al. Thr203 of claudin-1, a putative phosphorylation site for MAP kinase, is required to promote the barrier function of tight junctions. Experimental Cell Research 2004, 295(1):36-47.
47. Fujita H., Chiba H., Yokozaki H., Sakai N., Sugimoto K., Wada T., et al. Differential expression and subcellular localization of claudin-7, -8, -12, -13, and -15 along the mouse intestine. The Journal of Histochemistry and Cytochemistry 2006, 54(8):933-944.
48. Gress T.M., Muller-Pillasch F., Geng M., Zimmerhackl F., Zehetner G., Friess H., et al. A pancreatic cancer-specific expression profile. Oncogene 1996, 13(8):1819-1830.
49. Grone J., Weber B., Staub E., Heinze M., Klaman I., Pilarsky C., et al. Differential expression of genes encoding tight junction proteins in colorectal cancer: Frequent dysregulation of claudin-1, -8 and -12. International Journal of Colorectal Disease 2007, 22(6):651-659.
50. Hahn H.P., Bundock E.A., Hornick J.L. Immunohistochemical staining for claudin-1 can help distinguish meningiomas from histologic mimics. American Journal of Clinical Pathology 2006, 125(2):203-208.
51. Hamazaki Y., Itoh M., Sasaki H., Furuse M., Tsukita S. Multi-PDZ domain protein 1 (MUPP1) is concentrated at tight junctions through its possible interaction with claudin-1 and junctional adhesion molecule. The Journal of Biological Chemistry 2002, 277(1):455-461.
52. Han X., Fink M.P., Delude R.L. Proinflammatory cytokines cause NO-dependent and -independent changes in expression and localization of tight junction proteins in intestinal epithelial cells. Shock 2003, 19(3):229-237.
53. Hanada S., Maeshima A., Matsuno Y., Ohta T., Ohki M., Yoshida T., et al. Expression profile of early lung adenocarcinoma: Identification of MRP3 as a molecular marker for early progression. The Journal of Pathology 2008, 216(1):75-82.
54. Heinzelmann-Schwarz V.A., Gardiner-Garden M., Henshall S.M., Scurry J., Scolyer R.A., Davies M.J., et al. Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clinical Cancer Research 2004, 10(13):4427-4436.
55. Hewitt K.J., Agarwal R., Morin P.J. The claudin gene family: Expression in normal and neoplastic tissues. BMC Cancer 2006, 6:186.
56. Hibbs K., Skubitz K.M., Pambuccian S.E., Casey R.C., Burleson K.M., Oegema T.R., et al. Differential gene expression in ovarian carcinoma: Identification of potential biomarkers. American Journal of Pathology 2004, 165(2):397-414.
57. Higashi Y., Suzuki S., Sakaguchi T., Nakamura T., Baba S., Reinecker H.C., et al. Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma. The Journal of Surgical Research 2007, 139(1):68-76.
58. Hoevel T., Macek R., Swisshelm K., Kubbies M. Reexpression of the TJ protein CLDN1 induces apoptosis in breast tumor spheroids. International Journal of Cancer 2004, 108(3):374-383.
59. Honda H., Pazin M.J., D'Souza T., Ji H., Morin P.J. Regulation of the CLDN3 gene in ovarian cancer cells. Cancer Biology & Therapy 2007, 6(11):1733-1742.
60. Honda H., Pazin M.J., Ji H., Wernyj R.P., Morin P.J. Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells. The Journal of Biological Chemistry 2006, 281(30):21433-21444.
61. Hornsby C.D., Cohen C., Amin M.B., Picken M.M., Lawson D., Yin-Goen Q., et al. Claudin-7 immunohistochemistry in renal tumors: A candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling. Archives of Pathology and Laboratory Medicine 2007, 131(10):1541-1546.
62. Hough C.D., Sherman-Baust C.A., Pizer E.S., Montz F.J., Im D.D., Rosenshein N.B., et al. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Research 2000, 60:6281-6287.
63. Huang Y.H., Bao Y., Peng W., Goldberg M., Love K., Bumcrot D.A., et al. Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(9):3426-3430.
64. Huo Q., Kinugasa T., Wang L., Huang J., Zhao J., Shibaguchi H., et al. Claudin-1 protein is a major factor involved in the tumorigenesis of colorectal cancer. Anticancer Research 2009, 29(3):851-857.
65. Ikari A., Atomi K., Takiguchi A., Yamazaki Y., Miwa M., Sugatani J. Epidermal growth factor increases claudin-4 expression mediated by Sp1 elevation in MDCK cells. Biochemical and Biophysical Research Communications 2009, 384(3):306-310.
66. Ikari A., Ito M., Okude C., Sawada H., Harada H., Degawa M., et al. Claudin-16 is directly phosphorylated by protein kinase A independently of a vasodilator-stimulated phosphoprotein-mediated pathway. Journal of Cellular Physiology 2008, 214(1):221-229.
67. Ikari A., Matsumoto S., Harada H., Takagi K., Hayashi H., Suzuki Y., et al. Phosphorylation of paracellin-1 at Ser217 by protein kinase A is essential for localization in tight junctions. Journal of Cell Science 2006, 119(Pt 9):1781-1789.
68. Ip Y.C., Cheung S.T., Lee Y.T., Ho J.C., Fan S.T. Inhibition of hepatocellular carcinoma invasion by suppression of claudin-10 in HLE cells. Molecular Cancer Therapeutics 2007, 6(11):2858-2867.
69. Ishida M., Kushima R., Okabe H. Claudin expression in rectal well-differentiated endocrine neoplasms (carcinoid tumors). Oncology Reports 2009, 21(1):113-117.
70. Ishizaki T., Chiba H., Kojima T., Fujibe M., Soma T., Miyajima H., et al. Cyclic AMP induces phosphorylation of claudin-5 immunoprecipitates and expression of claudin-5 gene in blood-brain-barrier endothelial cells via protein kinase A-dependent and -independent pathways. Experimental Cell Research 2003, 290(2):275-288.
71. Itoh M., Furuse M., Morita K., Kubota K., Saitou M., Tsukita S. Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins. The Journal of Cell Biology 1999, 147(6):1351-1363.
72. Johnson A.H., Frierson H.F., Zaika A., Powell S.M., Roche J., Crowe S., et al. Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis. American Journal of Pathology 2005, 167(2):577-584.
73. Jung J.H., Jung C.K., Choi H.J., Jun K.H., Yoo J., Kang S.J., et al. Diagnostic utility of expression of claudins in non-small cell lung cancer: Different expression profiles in squamous cell carcinomas and adenocarcinomas. Pathology, Research and Practice 2009, 205(6):409-416.
74. Kamata I., Ishikawa Y., Akishima-Fukasawa Y., Ito K., Akasaka Y., Uzuki M., et al. Significance of lymphatic invasion and cancer invasion-related proteins on lymph node metastasis in gastric cancer. Journal of Gastroenterology and Hepatology 2009, 24(9):1527-1533.
75. Karanjawala Z.E., Illei P.B., Ashfaq R., Infante J.R., Murphy K., Pandey A., et al. New markers of pancreatic cancer identified through differential gene expression analyses: Claudin 18 and annexin A8. American Journal of Surgical Pathology 2008, 32(2):188-196.
76. Katahira J., Inoue N., Horiguchi Y., Matsuda M., Sugimoto N. Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. The Journal of Cell Biology 1997, 136(6):1239-1247.
77. Katahira J., Sugiyama H., Inoue N., Horiguchi Y., Matsuda M., Sugimoto N. Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. The Journal of Biological Chemistry 1997, 272(42):26652-26658.
78. Katoh M., Katoh M. CLDN23 gene, frequently down-regulated in intestinal-type gastric cancer, is a novel member of CLAUDIN gene family. International Journal of Molecular Medicine 2003, 11(6):683-689.
79. Kim S.S., Choi Y.D., Jin X.M., Cho Y.M., Jang J.J., Juhng S.W., et al. Immunohistochemical stain for cytokeratin 7, S100A1 and claudin 8 is valuable in differential diagnosis of chromophobe renal cell carcinoma from renal oncocytoma. Histopathology 2009, 54(5):633-635.
80. Kim T.H., Huh J.H., Lee S., Kang H., Kim G.I., An H.J. Down-regulation of claudin-2 in breast carcinomas is associated with advanced disease. Histopathology 2008, 53(1):48-55.
81. Kinugasa T., Huo Q., Higashi D., Shibaguchi H., Kuroki M., Tanaka T., et al. Selective up-regulation of claudin-1 and claudin-2 in colorectal cancer. Anticancer Research 2007, 27(6A):3729-3734.
82. Kinugasa T., Sakaguchi T., Gu X., Reinecker H.C. Claudins regulate the intestinal barrier in response to immune mediators. Gastroenterology 2000, 118(6):1001-1011.
83. Kitajiri S.I., Furuse M., Morita K., Saishin-Kiuchi Y., Kido H., Ito J., et al. Expression patterns of claudins, tight junction adhesion molecules, in the inner ear. Hearing Research 2004, 187(1-2):25-34.
84. Kiuchi-Saishin Y., Gotoh S., Furuse M., Takasuga A., Tano Y., Tsukita S. Differential expression patterns of claudins, tight junction membrane proteins, in mouse nephron segments. Journal of the American Society of Nephrology 2002, 13(4):875-886.
85. Kleinberg L., Holth A., Fridman E., Schwartz I., Shih Ie M., Davidson B. The diagnostic role of claudins in serous effusions. American Journal of Clinical Pathology 2007, 127(6):928-937.
86. Kleinberg L., Holth A., Trope C.G., Reich R., Davidson B. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Human Pathology 2008, 39(5):747-757.
87. Kominsky S.L. Claudins: Emerging targets for cancer therapy. Expert Reviews in Molecular Medicine 2006, 8(18):1-11.
88. Kominsky S.L., Argani P., Korz D., Evron E., Raman V., Garrett E., et al. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003, 22(13):2021-2033.
89. Kominsky S.L., Tyler B., Sosnowski J., Brady K., Doucet M., Nell D., et al. Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Research 2007, 67(17):7977-7982.
90. Kominsky S.L., Vali M., Korz D., Gabig T.G., Weitzman S.A., Argani P., et al. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. American Journal of Pathology 2004, 164(5):1627-1633.
91. Kondo J., Sato F., Kusumi T., Liu Y., Motonari O., Sato T., et al. Claudin-1 expression is induced by tumor necrosis factor-alpha in human pancreatic cancer cells. International Journal of Mol Med 2008, 22(5):645-649.
92. Konecny G.E., Agarwal R., Keeney G.A., Winterhoff B., Jones M.B., Mariani A., et al. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecologic Oncology 2008, 109(2):263-269.
93. Kramer F., White K., Kubbies M., Swisshelm K., Weber B.H. Genomic organization of claudin-1 and its assessment in hereditary and sporadic breast cancer. Human Genetics 2000, 107(3):249-256.
94. Krause G., Winkler L., Mueller S.L., Haseloff R.F., Piontek J., Blasig I.E. Structure and function of claudins. Biochimica et Biophysica Acta 2008, 1778(3):631-645.
95. Kuhn S., Koch M., Nubel T., Ladwein M., Antolovic D., Klingbeil P., et al. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Molecular Cancer Research 2007, 5(6):553-567.
96. Kulka J., Szasz A.M., Nemeth Z., Madaras L., Schaff Z., Molnar I.A., et al. Expression of tight junction protein claudin-4 in basal-like breast carcinomas. Pathology and Oncology Research 2009, 15(1):59-64.
97. Kumei S., Motomura W., Yoshizaki T., Takakusaki K., Okumura T. Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells. Biochemical and Biophysical Research Communications 2009, 380(3):614-619.
98. Ladwein M., Pape U.F., Schmidt D.S., Schnolzer M., Fiedler S., Langbein L., et al. The cell-cell adhesion molecule EpCAM interacts directly with the tight junction protein claudin-7. Experimental Cell Research 2005, 309(2):345-357.
99. Lal-Nag M., Morin P.J. The claudins. Genome Biology 2009, 10(8):235.
100. Landers K.A., Samaratunga H., Teng L., Buck M., Burger M.J., Scells B., et al. Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. British Journal of Cancer 2008, 99(3):491-501.
101. Lanigan F., McKiernan E., Brennan D.J., Hegarty S., Millikan R.C., McBryan J., et al. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. International Journal of Cancer 2009, 124(9):2088-2097.
102. Lechpammer M., Resnick M.B., Sabo E., Yakirevich E., Greaves W.O., Sciandra K.T., et al. The diagnostic and prognostic utility of claudin expression in renal cell neoplasms. Modern Pathology 2008, 21(11):1320-1329.
103. Lee J.W., Hsiao W.T., Chen H.Y., Hsu L.P., Chen P.R., Lin M.D., et al. Up-regulated claudin-1 expression confers resistance to cell death of nasopharyngeal carcinoma cells. International Journal of Cancer 2010, 126(6):1353-1366.
104. Lee J.W., Lee S.J., Seo J., Song S.Y., Ahn G., Park C.S., et al. Increased expressions of claudin-1 and claudin-7 during the progression of cervical neoplasia. Gynecologic Oncology 2005, 97(1):53-59.
105. Lee S.K., Moon J., Park S.W., Song S.Y., Chung J.B., Kang J.K. Loss of the tight junction protein claudin 4 correlates with histological growth-pattern and differentiation in advanced gastric adenocarcinoma. Oncol Rep 2005, 13(2):193-199.
106. Lee L.Y., Wu C.M., Wang C.C., Yu J.S., Liang Y., Huang K.H., et al. Expression of matrix metalloproteinases MMP-2 and MMP-9 in gastric cancer and their relation to claudin-4 expression. Histology and Histopathology 2008, 23(5):515-521.
107. Leotlela P.D., Wade M.S., Duray P.H., Rhode M.J., Brown H.F., Rosenthal D.T., et al. Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene 2007, 26(26):3846-3856.
108. Li J., Chigurupati S., Agarwal R., Mughal M.R., Mattson M.P., Becker K.G., et al. Possible angiogenic roles for claudin-4 in ovarian cancer. Cancer Biology & Therapy 2009, 8(19):1806-1814.
109. Li W.Y., Huey C.L., Yu A.S. Expression of claudin-7 and -8 along the mouse nephron. American Journal of Physical-Renal Physiology 2004, 286(6):F1063-F1071.
110. Li J., Sherman-Baust C.A., Tsai-Turton M., Bristow R.E., Roden R.B., Morin P.J. Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer 2009, 9:244.
111. Li L., Yao J.L., di Sant'agnese P.A., Bourne P.A., Picken M.M., Young A.N., et al. Expression of claudin-7 in benign kidney and kidney tumors. International Journal of Clinical and Experimental Pathology 2008, 1(1):57-64.
112. Lioni M., Brafford P., Andl C., Rustgi A., El-Deiry W., Herlyn M., et al. Dysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cells. American Journal of Pathology 2007, 170(2):709-721.
113. Lipschutz J.H., Li S., Arisco A., Balkovetz D.F. Extracellular signal-regulated kinases 1/2 control claudin-2 expression in Madin-Darby canine kidney strain I and II cells. The Journal of Biological Chemistry 2005, 280(5):3780-3788.
114. Litkouhi B., Kwong J., Lo C.M., Smedley III, McClane B.A., Aponte M., et al. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 2007, 9(4):304-314.
115. Liu Y., Sun W., Zhang K., Zheng H., Ma Y., Lin D., et al. Identification of genes differentially expressed in human primary lung squamous cell carcinoma. Lung Cancer 2007, 56(3):307-317.
116. Lodi C., Szabo E., Holczbauer A., Batmunkh E., Szijarto A., Kupcsulik P., et al. Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas. Modern Pathology 2006, 19(3):460-469.
117. Long H., Crean C.D., Lee W.H., Cummings O.W., Gabig T.G. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Research 2001, 61(21):7878-7881.
118. Lopardo T., Lo Iacono N., Marinari B., Giustizieri M.L., Cyr D.G., Merlo G., et al. Claudin-1 is a p63 target gene with a crucial role in epithelial development. PLoS ONE 2008, 3(7):e2715.
119. Lu K.H., Patterson A.P., Wang L., Marquez R.T., Atkinson E.N., Baggerly K.A., et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clinical Cancer Research 2004, 10(10):3291-3300.
120. Martin T.A., Harrison G.M., Watkins G., Jiang W.G. Claudin-16 reduces the aggressive behavior of human breast cancer cells. Journal of Cellular Biochemistry 2008, 105(1):41-52.
121. Martin T.A., Watkins G., Mansel R.E., Jiang W.G. Hepatocyte growth factor disrupts tight junctions in human breast cancer cells. Cell Biology International 2004, 28(5):361-371.
122. Martinez-Estrada O.M., Culleres A., Soriano F.X., Peinado H., Bolos V., Martinez F.O., et al. The transcription factors Slug and Snail act as repressors of Claudin-1 expression in epithelial cells. Biochemical Journal 2006, 394(Pt 2):449-457.
123. Martins F.C., Teixeira F., Reis I., Geraldes N., Cabrita A.M., Dias M.F. Increased transglutaminase 2 and GLUT-1 expression in breast tumors not susceptible to chemoprevention with antioxidants. Tumori 2009, 95(2):227-232.
124. Matsuda Y., Semba S., Ueda J., Fuku T., Hasuo T., Chiba H., et al. Gastric and intestinal claudin expression at the invasive front of gastric carcinoma. Cancer Science 2007, 98(7):1014-1019.
125. McClane B.A. Clostridium perfringens enterotoxin and intestinal tight junctions. Trends in Microbiology 2000, 8(4):145-146.
126. McClane B.A., Hanna P.C., Wnek A.P. Clostridium perfringens enterotoxin. Microbial Pathogenesis 1988, 4(5):317-323.
127. Mees S.T., Mennigen R., Spieker T., Rijcken E., Senninger N., Haier J., et al. Expression of tight and adherens junction proteins in ulcerative colitis associated colorectal carcinoma: Upregulation of claudin-1, claudin-3, claudin-4, and beta-catenin. International Journal of Colorectal Disease 2009, 24(4):361-368.
128. Michl P., Barth C., Buchholz M., Lerch M.M., Rolke M., Holzmann K.H., et al. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Research 2003, 63(19):6265-6271.
129. Mima S., Tsutsumi S., Ushijima H., Takeda M., Fukuda I., Yokomizo K., et al. Induction of claudin-4 by nonsteroidal anti-inflammatory drugs and its contribution to their chemopreventive effect. Cancer Research 2005, 65(5):1868-1876.
130. Mima S., Takehara M., Takada H., Nishimura T., Hoshino T., Mizushima T. NSAIDs suppress the expression of claudin-2 to promote invasion activity of cancer cells. Carcinogenesis 2008, 29(10):1994-2000.
131. Mittal M.K., Myers J.N., Bailey C.K., Misra S., Chaudhuri G. Mode of action of the retrogene product SNAI1P, a SNAIL homolog, in human breast cancer cells. Molecular Biology Reports 2010, 37(3):1221-1227.
132. Miwa N., Furuse M., Tsukita S., Niikawa N., Nakamura Y., Furukawa Y. Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. Oncology Research 2001, 12(11-12):469-476.
133. Miyamori H., Takino T., Kobayashi Y., Tokai H., Itoh Y., Seiki M., et al. Claudin promotes activation of pro-matrix metalloproteinase-2 mediated by membrane-type matrix metalloproteinases. The Journal of Biological Chemistry 2001, 276(30):28204-28211.
134. Miyamoto K., Kusumi T., Sato F., Kawasaki H., Shibata S., Ohashi M., et al. Decreased expression of claudin-1 is correlated with recurrence status in esophageal squamous cell carcinoma. Biomedical Research 2008, 29(2):71-76.
135. Moldvay J., Jackel M., Paska C., Soltesz I., Schaff Z., Kiss A. Distinct claudin expression profile in histologic subtypes of lung cancer. Lung Cancer 2007, 57(2):159-167.
136. Montgomery E., Mamelak A.J., Gibson M., Maitra A., Sheikh S., Amr S.S., et al. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions. Applied Immunohistochemistry & Molecular Morphology 2006, 14(1):24-30.
137. Morin P.J. Claudin proteins in human cancer: Promising new targets for diagnosis and therapy. Cancer Research 2005, 65(21):9603-9606.
138. Morin P.J. Claudin proteins in ovarian cancer. Disease Markers 2007, 23(5-6):453-457.
139. Morita K., Morita N.I., Nemoto K., Nakamura Y., Miyachi Y., Muto M. Expression of claudin in melanoma cells. The Journal of Dermatology 2008, 35(1):36-38.
140. Morita K., Tsukita S., Miyachi Y. Tight junction-associated proteins (occludin, ZO-1, claudin-1, claudin-4) in squamous cell carcinoma and Bowen's disease. British Journal of Dermatology 2004, 151(2):328-334.
141. Morohashi S., Kusumi T., Sato F., Odagiri H., Chiba H., Yoshihara S., et al. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. International Journal of Molecular Medicine 2007, 20(2):139-143.
142. Nakanishi K., Ogata S., Hiroi S., Tominaga S., Aida S., Kawai T. Expression of occludin and claudins 1, 3, 4, and 7 in urothelial carcinoma of the upper urinary tract. American Journal of Clinical Pathology 2008, 130(1):43-49.
143. Nakayama F., Semba S., Usami Y., Chiba H., Sawada N., Yokozaki H. Hypermethylation-modulated downregulation of claudin-7 expression promotes the progression of colorectal carcinoma. Pathobiology 2008, 75(3):177-185.
144. Nemeth Z., Szasz A.M., Tatrai P., Nemeth J., Gyorffy H., Somoracz A., et al. Claudin-1, -2, -3, -4, -7, -8, and -10 protein expression in biliary tract cancers. The Journal of Histochemistry and Cytochemistry 2009, 57(2):113-121.
145. Nichols L.S., Ashfaq R., Iacobuzio-Donahue C.A. Claudin 4 protein expression in primary and metastatic pancreatic cancer: Support for use as a therapeutic target. American Journal of Clinical Pathology 2004, 121(2):226-230.
146. Nishino R., Honda M., Yamashita T., Takatori H., Minato H., Zen Y., et al. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. Journal of Hepatology 2008, 49(2):207-216.
147. Nubel T., Preobraschenski J., Tuncay H., Weiss T., Kuhn S., Ladwein M., et al. Claudin-7 regulates EpCAM-mediated functions in tumor progression. Molecular Cancer Research 2009, 7(3):285-299.
148. Nunbhakdi-Craig V., Craig L., Machleidt T., Sontag E. Simian virus 40 small tumor antigen induces deregulation of the actin cytoskeleton and tight junctions in kidney epithelial cells. Journal of Virology 2003, 77(5):2807-2818.
149. Nunbhakdi-Craig V., Machleidt T., Ogris E., Bellotto D., White III, Sontag E. Protein phosphatase 2A associates with and regulates atypical PKC and the epithelial tight junction complex. The Journal of Cell Biology 2002, 158(5):967-978.
150. Offner S., Hekele A., Teichmann U., Weinberger S., Gross S., Kufer P., et al. Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy. Cancer Immunology, Immunotherapy 2005, 54(5):431-445.
151. Ohtani S., Terashima M., Satoh J., Soeta N., Saze Z., Kashimura S., et al. Expression of tight-junction-associated proteins in human gastric cancer: Downregulation of claudin-4 correlates with tumor aggressiveness and survival. Gastric Cancer 2009, 12(1):43-51.
152. Oku N., Sasabe E., Ueta E., Yamamoto T., Osaki T. Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Research 2006, 66(10):5251-5257.
153. Osanai M., Murata M., Chiba H., Kojima T., Sawada N. Epigenetic silencing of claudin-6 promotes anchorage-independent growth of breast carcinoma cells. Cancer Science 2007, 98(10):1557-1562.
154. Oshima T., Kunisaki C., Yoshihara K., Yamada R., Yamamoto N., Sato T., et al. Reduced expression of the claudin-7 gene correlates with venous invasion and liver metastasis in colorectal cancer. Oncology Reports 2008, 19(4):953-959.
155. Oshima T., Miwa H., Joh T. Aspirin induces gastric epithelial barrier dysfunction by activating p38 MAPK via claudin-7. American Journal of Physiology Cell Physiology 2008, 295(3):C800-C806.
156. Osunkoya A.O., Cohen C., Lawson D., Picken M.M., Amin M.B., Young A.N. Claudin-7 and claudin-8: Immunohistochemical markers for the differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma. Human Pathology 2009, 40(2):206-210.
157. Pan X.Y., Wang B., Che Y.C., Weng Z.P., Dai H.Y., Peng W. Expression of claudin-3 and claudin-4 in normal, hyperplastic, and malignant endometrial tissue. International Journal of Gynecological Cancer 2007, 17(1):233-241.
158. Park D., Karesen R., Axcrona U., Noren T., Sauer T. Expression pattern of adhesion molecules (E-cadherin, alpha-, beta-, gamma-catenin and claudin-7), their influence on survival in primary breast carcinoma, and their corresponding axillary lymph node metastasis. Apmis 2007, 115(1):52-65.
159. Park J.Y., Park K.H., Oh T.Y., Hong S.P., Jeon T.J., Kim C.H., et al. Up-regulated claudin 7 expression in intestinal-type gastric carcinoma. Oncology Reports 2007, 18(2):377-382.
160. Paschoud S., Bongiovanni M., Pache J.C., Citi S. Claudin-1 and claudin-5 expression patterns differentiate lung squamous cell carcinomas from adenocarcinomas. Modern Pathology 2007, 20(9):947-954.
161. Peter Y., Comellas A., Levantini E., Ingenito E.P., Shapiro S.D. Epidermal growth factor receptor and claudin-2 participate in A549 permeability and remodeling: Implications for non-small cell lung cancer tumor colonization. Molecular Carcinogenesis 2009, 48(6):488-497.
162. Piontek J., Winkler L., Wolburg H., Muller S.L., Zuleger N., Piehl C., et al. Formation of tight junction: Determinants of homophilic interaction between classic claudins. FASEB Journal 2008, 22(1):146-158.
163. Quan C., Lu S.J. Identification of genes preferentially expressed in mammary epithelial cells of Copenhagen rat using subtractive hybridization and microarrays. Carcinogenesis 2003, 24(10):1593-1599.
164. Rajaram V., Brat D.J., Perry A. Anaplastic meningioma versus meningeal hemangiopericytoma: Immunohistochemical and genetic markers. Human Pathology 2004, 35(11):1413-1418.
165. Rangel L.B.A., Agarwal R., D'Souza T., Pizer E.S., Alò P.L., Lancaster W.D., et al. Tight junction proteins Claudin-3 and Claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clinical Cancer Research 2003, 9:2567-2575.
166. Rangel L.B.A., Sherman-Baust C.A., Wernyj R.P., Schwartz D.R., Cho K.R., Morin P.J. Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression. Oncogene 2003, 22:7225-7232.
167. Resnick M.B., Gavilanez M., Newton E., Konkin T., Bhattacharya B., Britt D.E., et al. Claudin expression in gastric adenocarcinomas: A tissue microarray study with prognostic correlation. Human Pathology 2005, 36(8):886-892.
168. Resnick M.B., Konkin T., Routhier J., Sabo E., Pricolo V.E. Claudin-1 is a strong prognostic indicator in stage II colonic cancer: A tissue microarray study. Modern Pathology 2005, 18(4):511-518.
169. Reyes J.L., Lamas M., Martin D., del Carmen Namorado M., Islas S., Luna J., et al. The renal segmental distribution of claudins changes with development. Kidney International 2002, 62(2):476-487.
170. Roh M.H., Liu C.J., Laurinec S., Margolis B. The carboxyl terminus of zona occludens-3 binds and recruits a mammalian homologue of discs lost to tight junctions. The Journal of Biological Chemistry 2002, 277(30):27501-27509.
171. Rohan S., Tu J.J., Kao J., Mukherjee P., Campagne F., Zhou X.K., et al. Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. Clinical Cancer Research 2006, 12(23):6937-6945.
172. Romani C., Comper F., Bandiera E., Ravaggi A., Bignotti E., Tassi R.A., et al. Development and characterization of a human single-chain antibody fragment against claudin-3: A novel therapeutic target in ovarian and uterine carcinomas. American Journal of Obstetrics and Gynecology 2009, 201(1):70e1. 70e9.
173. Rosen D.G., Wang L., Atkinson J.N., Yu Y., Lu K.H., Diamandis E.P., et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecologic Oncology 2005, 99(2):267-277.
174. Roth M.J., Abnet C.C., Hu N., Wang Q.H., Wei W.Q., Green L., et al. p16, MGMT, RARbeta2, CLDN3, CRBP and MT1G gene methylation in esophageal squamous cell carcinoma and its precursor lesions. Oncology Reports 2006, 15(6):1591-1597.
175. Saeki R., Kondoh M., Kakutani H., Tsunoda S., Mochizuki Y., Hamakubo T., et al. A novel tumor-targeted therapy using a claudin-4-targeting molecule. Molecular Pharmacology 2009, 76(4):918-926.
176. Sakai N., Chiba H., Fujita H., Akashi Y., Osanai M., Kojima T., et al. Expression patterns of claudin family of tight-junction proteins in the mouse prostate. Histochemistry and Cell Biology 2007, 127(4):457-462.
177. Sanada Y., Oue N., Mitani Y., Yoshida K., Nakayama H., Yasui W. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. The Journal of Pathology 2006, 208(5):633-642.
178. Santin A.D., Bellone S., Marizzoni M., Palmieri M., Siegel E.R., McKenney J.K., et al. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: Novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). Cancer 2007, 109(7):1312-1322.
179. Santin A.D., Bellone S., Siegel E.R., McKenney J.K., Thomas M., Roman J.J., et al. Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas. Clinical Cancer Research 2007, 13(11):3339-3346.
180. Santin A.D., Cane S., Bellone S., Palmieri M., Siegel E.R., Thomas M., et al. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Research 2005, 65(10):4334-4342.
181. Santin A.D., Zhan F., Bellone S., Palmieri M., Cane S., Bignotti E., et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy. International Journal of Cancer 2004, 112(1):14-25.
182. Santin A.D., Zhan F., Cane S., Bellone S., Palmieri M., Thomas M., et al. Gene expression fingerprint of uterine serous papillary carcinoma: Identification of novel molecular markers for uterine serous cancer diagnosis and therapy. British Journal of Cancer 2005, 92(8):1561-1573.
183. Satake S., Semba S., Matsuda Y., Usami Y., Chiba H., Sawada N., et al. Cdx2 transcription factor regulates claudin-3 and claudin-4 expression during intestinal differentiation of gastric carcinoma. Pathology International 2008, 58(3):156-163.
184. Sato N., Fukushima N., Maitra A., Iacobuzio-Donahue C.A., van Heek N.T., Cameron J.L., et al. Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. American Journal of Pathology 2004, 164(3):903-914.
185. Sauer T., Pedersen M.K., Ebeltoft K., Naess O. Reduced expression of Claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease. Cytopathology 2005, 16(4):193-198.
186. Schuetz A.N., Yin-Goen Q., Amin M.B., Moreno C.S., Cohen C., Hornsby C.D., et al. Molecular classification of renal tumors by gene expression profiling. The Journal of Molecular Diagnostics 2005, 7(2):206-218.
187. Semba S., Hasuo T., Satake S., Nakayama F., Yokozaki H. Prognostic significance of intestinal claudins in high-risk synchronous and metachronous multiple gastric epithelial neoplasias after initial endoscopic submucosal dissection. Pathology International 2008, 58(6):371-377.
188. Sentani K., Oue N., Tashiro T., Sakamoto N., Nishisaka T., Fukuhara T., et al. Immunohistochemical staining of Reg IV and claudin-18 is useful in the diagnosis of gastrointestinal signet ring cell carcinoma. American Journal of Surgical Pathology 2008, 32(8):1182-1189.
189. Sheehan G.M., Kallakury B.V., Sheehan C.E., Fisher H.A., Kaufman R.P., Ross J.S. Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Human Pathology 2007, 38(4):564-569.
190. Shiou S.R., Singh A.B., Moorthy K., Datta P.K., Washington M.K., Beauchamp R.D., et al. Smad4 regulates claudin-1 expression in a transforming growth factor-beta-independent manner in colon cancer cells. Cancer Research 2007, 67(4):1571-1579.
191. Singh A.B., Harris R.C. Epidermal growth factor receptor activation differentially regulates claudin expression and enhances transepithelial resistance in Madin-Darby canine kidney cells. The Journal of Biological Chemistry 2004, 279(5):3543-3552.
192. Sobel G., Nemeth J., Kiss A., Lotz G., Szabo I., Udvarhelyi N., et al. Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma. Gynecologic Oncology 2006, 103(2):591-598.
193. Sobel G., Paska C., Szabo I., Kiss A., Kadar A., Schaff Z. Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma. Human Pathology 2005, 36(2):162-169.
194. Sobel G., Szabo I., Paska C., Kiss A., Kovalszky I., Kadar A., et al. Changes of cell adhesion and extracellular matrix (ECM) components in cervical intraepithelial neoplasia. Pathology Oncology Research 2005, 11(1):26-31.
195. Soini Y. Claudins 2, 3, 4, and 5 in Paget's disease and breast carcinoma. Human Pathology 2004, 35(12):1531-1536.
196. Soini Y., Talvensaari-Mattila A. Expression of claudins 1, 4, 5, and 7 in ovarian tumors of diverse types. International Journal of Gynecological Pathology 2006, 25(4):330-335.
197. Soini Y., Kinnula V., Kahlos K., Paakko P. Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura. Journal of Clinical Pathology 2006, 59(3):250-254.
198. Soini Y., Tommola S., Helin H., Martikainen P. Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Archiv 2006, 448(1):52-58.
199. Soma T., Chiba H., Kato-Mori Y., Wada T., Yamashita T., Kojima T., et al. Thr(207) of claudin-5 is involved in size-selective loosening of the endothelial barrier by cyclic AMP. Experimental Cell Research 2004, 300(1):202-212.
200. Song X., Li X., Tang Y., Chen H., Wong B., Wang J., et al. Expression of claudin-2 in the multistage process of gastric carcinogenesis. Histology and Histopathology 2008, 23(6):673-682.
201. Steinau M., Rajeevan M.S., Lee D.R., Ruffin M.T., Horowitz I.R., Flowers L.C., et al. Evaluation of RNA markers for early detection of cervical neoplasia in exfoliated cervical cells. Cancer Epidemiology, Biomarkers and Prevention 2007, 16(2):295-301.
202. Stewart J.J., White J.T., Yan X., Collins S., Drescher C.W., Urban N.D., et al. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Molecular & Cellular Proteomics 2006, 5(3):433-443.
203. Suzuki M., Kato-Nakano M., Kawamoto S., Furuya A., Abe Y., Misaka H., et al. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers. Cancer Science 2009, 100(9):1623-1630.
204. Szabo I., Kiss A., Schaff Z., Sobel G. Claudins as diagnostic and prognostic markers in gynecological cancer. Histology and Histopathology 2009, 24(12):1607-1615.
205. Szasz A.M., Nyirady P., Majoros A., Szendroi A., Szucs M., Szekely E., et al. Beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression. BJU International 2009.
206. Takala H., Saarnio J., Wiik H., Soini Y. Claudins 1, 3, 4, 5 and 7 in esophageal cancer: Loss of claudin 3 and 4 expression is associated with metastatic behavior. Apmis 2007, 115(7):838-847.
207. Takehara M., Nishimura T., Mima S., Hoshino T., Mizushima T. Effect of claudin expression on paracellular permeability, migration and invasion of colonic cancer cells. Biological and Pharmaceutical Bulletin 2009, 32(5):825-831.
208. Tanaka M., Kamata R., Sakai R. EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates paracellular permeability. The Journal of Biological Chemistry 2005, 280(51):42375-42382.
209. Tassi R.A., Bignotti E., Falchetti M., Ravanini M., Calza S., Ravaggi A., et al. Claudin-7 expression in human epithelial ovarian cancer. International Journal of Gynecological Cancer 2008, 18(6):1262-1271.
210. Tatum R., Zhang Y., Lu Q., Kim K., Jeansonne B.G., Chen Y.H. WNK4 phosphorylates ser(206) of claudin-7 and promotes paracellular Cl(-) permeability. FEBS Letters 2007, 581(20):3887-3891.
211. Terris B., Blaveri E., Crnogorac-Jurcevic T., Jones M., Missiaglia E., Ruszniewski P., et al. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. American Journal of Pathology 2002, 160(5):1745-1754.
212. Thway K., Fisher C., Debiec-Rychter M., Calonje E. Claudin-1 is expressed in perineurioma-like low-grade fibromyxoid sarcoma. Human Pathology 2009, 40(11):1586-1590.
213. Tokes A.M., Kulka J., Paku S., Szik A., Paska C., Novak P.K., et al. Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: A research study. Breast Cancer Research 2005, 7(2):R296-R305.
214. Tsukahara M., Nagai H., Kamiakito T., Kawata H., Takayashiki N., Saito K., et al. Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas. Pathology International 2005, 55(2):63-69.
215. Tsukita S., Furuse M. Pores in the wall: Claudins constitute tight junction strands containing aqueous pores. The Journal of Cell Biology 2000, 149(1):13-16.
216. Tzelepi V.N., Tsamandas A.C., Vlotinou H.D., Vagianos C.E., Scopa C.D. Tight junctions in thyroid carcinogenesis: Diverse expression of claudin-1, claudin-4, claudin-7 and occludin in thyroid neoplasms. Modern Pathology 2008, 21(1):22-30.
217. Ueda J., Semba S., Chiba H., Sawada N., Seo Y., Kasuga M., et al. Heterogeneous expression of claudin-4 in human colorectal cancer: Decreased claudin-4 expression at the invasive front correlates cancer invasion and metastasis. Pathobiology 2007, 74(1):32-41.
218. Usami Y., Chiba H., Nakayama F., Ueda J., Matsuda Y., Sawada N., et al. Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus. Human Pathology 2006, 37(5):569-577.
219. Usami Y., Satake S., Nakayama F., Matsumoto M., Ohnuma K., Komori T., et al. Snail-associated epithelial-mesenchymal transition promotes oesophageal squamous cell carcinoma motility and progression. The Journal of Pathology 2008, 215(3):330-339.
220. Van Itallie C.M., Anderson J.M. Claudins and epithelial paracellular transport. Annual Review of Physiology 2006, 68:403-429.
221. Van Itallie C.M., Gambling T.M., Carson J.L., Anderson J.M. Palmitoylation of claudins is required for efficient tight-junction localization. Journal of Cell Science 2005, 118(Pt 7):1427-1436.
222. Vare P., Loikkanen I., Hirvikoski P., Vaarala M.H., Soini Y. Low claudin expression is associated with high Gleason grade in prostate adenocarcinoma. Oncology Reports 2008, 19(1):25-31.
223. Vazquez-Ortiz G., Ciudad C.J., Pina P., Vazquez K., Hidalgo A., Alatorre B., et al. Gene identification by cDNA arrays in HPV-positive cervical cancer. Archives of Medical Research 2005, 36(5):448-458.
224. Vincent T., Neve E.P., Johnson J.R., Kukalev A., Rojo F., Albanell J., et al. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition. Nature Cell Biology 2009, 11(8):943-950.
225. Weber C.R., Nalle S.C., Tretiakova M., Rubin D.T., Turner J.R. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Laboratory Investigation 2008, 88(10):1110-1120.
226. Wu X., Chen H., Parker B., Rubin E., Zhu T., Lee J.S., et al. HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Research 2006, 66(19):9527-9534.
227. Wu C.M., Lee Y.S., Wang T.H., Lee L.Y., Kong W.H., Chen E.S., et al. Identification of differential gene expression between intestinal and diffuse gastric cancer using cDNA microarray. Oncology Reports 2006, 15(1):57-64.
228. Wu Y.L., Zhang S., Wang G.R., Chen Y.P. Expression transformation of claudin-1 in the process of gastric adenocarcinoma invasion. World Journal of Gastroenterology 2008, 14(31):4943-4948.
229. Yamamoto T., Kojima T., Murata M., Takano K., Go M., Chiba H., et al. IL-1beta regulates expression of Cx32, occludin, and claudin-2 of rat hepatocytes via distinct signal transduction pathways. Experimental Cell Research 2004, 299(2):427-441.
230. Yamamoto M., Ramirez S.H., Sato S., Kiyota T., Cerny R.L., Kaibuchi K., et al. Phosphorylation of claudin-5 and occludin by rho kinase in brain endothelial cells. American Journal of Pathology 2008, 172(2):521-533.
231. Yamauchi K., Rai T., Kobayashi K., Sohara E., Suzuki T., Itoh T., et al. Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates claudins. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(13):4690-4694.
232. Yasui W., Oue N., Sentani K., Sakamoto N., Motoshita J. Transcriptome dissection of gastric cancer: Identification of novel diagnostic and therapeutic targets from pathology specimens. Pathology International 2009, 59(3):121-136.
233. Yuan X., Lin X., Manorek G., Kanatani I., Cheung L.H., Rosenblum M.G., et al. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Molecular Cancer Therapeutics 2009, 8(7):1906-1915.
234. Zhang K., Yao H.P., Wang M.H. Activation of RON differentially regulates claudin expression and localization: Role of claudin-1 in RON-mediated epithelial cell motility. Carcinogenesis 2008, 29(3):552-559.
235. Zhu Y., Brannstrom M., Janson P.O., Sundfeldt K. Differences in expression patterns of the tight junction proteins, claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. International Journal of Cancer 2006, 118(8):1884-1891.